Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy

Transplantation

Volumn 66, Issue 12, 1998, Pages 1780-1786

  Turgeon, Nathalie ^a   Fishman, Jay A ^a   Basgoz, Nesli ^a   Tolkoff Rubin, Nina E ^a   Doran, Maureen ^c   Cosimi, A Benedict ^a   Rubin, Robert H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Inst of Technology ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; LYMPHOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACYCLOVIR; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIGENS, VIRAL; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; VIREMIA;

EID: 0032573686     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00036     Document Type: Article

References (27)

1. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12: S754.
2. Suwansirikul S, Rao N, Dowling JN, Ho M. Primary and secondary cytomegalovirus infection. Arch Intern Med 1977; 137: 1026.
3. Chatterjee SN, Fiala M, Weiner J, et al. Primary cytomegalovirus and opportunistic infections. JAMA 1978; 240: 2446.
4. Mañez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462.
5. Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981; 305: 57.
6. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53: 68.
7. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995; 123: 18.
8. Nicol DL, MacDonald AS, Belitsky P, et al. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 1993; 55: 841.
9. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
10. Rubin, RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. Ed 3. New York: Plenum; 1994: 629.
11. Balfour HH, Chace BA, Stapleton JT, et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381.
12. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69.
13. Mazzulli T, Rubin RH, Ferraro MJ, et al. Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol 1993; 31: 2824.
14. Delmonico FL, Tolkoff-Rubin NE, Auchincloss Jr H, et al. Management of the renal allograft recipient: immunosuppressive protocols for long-term success. Clin Transplant 1994; 8: 34.
15. Gilbert JR, Pascual M, Schoenfeld DA, et al. Evolving trends in liver transplantation: an outcome and charge analysis. Transplantation, in press.
16. Cheeseman SH, Rubin RH, Stewart JA, et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. N Engl J Med 1979; 300: 1345.
17. Hirsch MS, Schooley RT, Cosimi AB, et al. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med 1983; 308: 1489.
18. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182.
19. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
20. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
21. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843.
22. Gane E, Saliba F, Valdecasas GJC, et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729.
23. Ahsan N, Holman MJ, Sonderbye L, et al. Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg bid and 500 mg bid). Transplant Proc 1998; 30: 1383.
24. Ahsan N, Holman MJ, and Yang HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transplant 1997; 11: 633.
25. Schafer P, Tenschert W, Gutenson K, Laufs R. Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay. J Clin Microbiol 1997; 35: 741.
26. Boeckh M, Woogerd PM, Stevens-Ayers T, et al. Factors influencing detection of quantitative cytomegalovirus antigenemia. J Clin Microbiol 1994; 32: 832.
27. Gotti E, Suter F, Baruzzo S, et al. Early ganciclovir therapy effectively controls viremia and avoids the need for prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin Transplant 1996; 10: 550.